Feb
6
11
Dr. Stephen Ferrara Appointed Principal Deputy Assistant Secretary of Defense for Health Affairs
Retired U.S. Navy captain and decorated physician welcomes new role to “accomplish together as we continue to advance the health and readiness of our force.”
Health.mil has undergone a recent update. For the best user experience we recommend clearing your browser cache.
The Pharmacovigilance Center (PVC) is an enterprise-level drug safety center supporting the Military Health System (MHS) and all Service branches. The PVC provides pharmacovigilance and pharmacoepidemiology analysis and develops best prescribing practices to reduce harm and improve outcomes. Our goal is to develop risk mitigation strategies to prevent adverse drug events which can occur when patients take medications.
To be the premier organization for the MHS promoting excellence in medication prescribing practices and reducing preventable adverse drug experiences for all our beneficiaries.
Provide data-driven evidence on medication safety, effectiveness, and best prescribing practices that serve as force multipliers directly contributing to keeping the warfighters and other beneficiaries healthy through policy guidance, strategic communication, and education worldwide.
The appearance of hyperlinks does not constitute endorsement by the Department of Defense of non-U.S. Government sites or the information, products, or services contained therein. Although the Defense Health Agency may or may not use these sites as additional distribution channels for Department of Defense information, it does not exercise editorial control over all of the information that you may find at these locations. Such links are provided consistent with the stated purpose of this website.